Table 2.
Efficacy of PI3K inhibitors in single-armed clinical trials with patients suffering from different subtypes of relapsed B-NHL
| Drug | Entity | Subgroups | Trial | Phase | Reference | n | % ORR | % CR |
|---|---|---|---|---|---|---|---|---|
| Copanlisib | i-B-NHL | SLL, FL, MZL, WM | NCT01660451 part B, CHRONOS 1 | II | 79 | 141 | 60 | 12 |
| FL | 104 | 59 | 14 | |||||
| Idelalisib | SLL, FL, MZL, WM | NCT01282424 | II | 80 | 125 | 57 | 6 | |
| FL | 72 | 54 | 8 | |||||
| Duvelisib | SLL, FL, MZL, WM | NCT01882803, DYNAMO | II | 88 | 129 | 47 | 1 | |
| FL | 83 | 43 | 1 | |||||
| Buparlisib | FL | NCT01693614 | II | 89 | 24 | 25 | 0 | |
| Copanlisib | DLBCL | All subtypes | NCT02391116 | II | 90 | 40 | 25 | 13 |
| ABC-DLBCL | 16 | 38 | 25 | |||||
| Idelalisib | All subtypes | NA | I | 91 | 9 | 0 | 0 | |
| Buparlisib | All subtypes | NCT01693614 | II | 89 | 26 | 12 | 4 | |
| Copanlisib | MCL | NCT01660451 part A | II | 85 | 11 | 64 | 18 | |
| Idelalisib | NCT00710528 | I | 92 | 40 | 40 | 5 | ||
| Buparlisib | NCT01693614 | II | 89 | 22 | 23 | 5 |
Notes: Entities investigated comprised indolent B-NHL and aggressive DLBCL and MCL. For each trial, the list contains the registration number at ClinicalTrials.gov and the corresponding reference. Results are indicated separately for all i-B-NHL or DLBCL and FL or ABC-DLBCL subgroups, respectively. Apart from the numbers of study participants, the percentages of ORR and CR are indicated. SLL has similar neoplastic B cells to CLL, but affects mostly lymph nodes.
Abbreviations: ABC, activated B cell; CR, complete remission; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; i-B-NHL, indolent B-cell non-Hodgkin lymphoma; MCL, mantle-cell lymphoma; MZL, marginal-zone lymphoma; NA, not applicable; ORR, overall response rate; SLL, small lymphocytic leukemia; WM, Waldenström macroglobulinemia.